Protein kinases

eFFECTOR Therapeutics to Present at JMP Securities 2021 Life Sciences Conference

Retrieved on: 
Monday, June 14, 2021

eFFECTOR is a clinical stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as selective translation regulator inhibitors.

Key Points: 
  • eFFECTOR is a clinical stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as selective translation regulator inhibitors.
  • eFFECTORs STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase 1/2 (MNK 1/2).
  • On May 26, 2021, eFFECTOR entered into the Merger Agreement with LWAC, a special purpose acquisition company, and Merger Sub, a wholly owned subsidiary of LWAC.
  • Neither LWAC nor eFFECTOR gives any assurance that either LWAC or eFFECTOR or the combined company will achieve its expectations.

TG Therapeutics Announces Data from a Phase 1 Study Evaluating TG-1701 as a Monotherapy and as a Triple Combination with Ublituximab and UKONIQ® at the 2021 European Hematology Association Virtual Congress

Retrieved on: 
Friday, June 11, 2021

Data from this trial were made available on demand this morning during the 3032 European Hematology Association (EHA) Virtual Congress.

Key Points: 
  • Data from this trial were made available on demand this morning during the 3032 European Hematology Association (EHA) Virtual Congress.
  • UKONIQ is a registered trademark of TG Therapeutics, Inc.
    UKONIQ is the first and onlyoral inhibitor of phosphoinositide 3 kinase (PI3K) delta and casein kinase 1(CK1) epsilon.
  • CK1-epsilonis a regulator of oncoprotein translation and has been implicated in the pathogenesis of cancer cells, including lymphoid malignancies.
  • Monitor for any new or worsening signs and symptoms of infection, including suspected PJP or CMV, during treatment with UKONIQ.

TG Therapeutics Announces Data from a Phase 1 Study Evaluating TG-1701 as a Monotherapy and as a Triple Combination with Ublituximab and UKONIQ® at the 2021 American Society of Clinical Oncology Annual Meeting

Retrieved on: 
Friday, June 4, 2021

Data from this trial were made available on demand this morning during the American Societyof Clinical Oncology (ASCO) Annual Meeting.

Key Points: 
  • Data from this trial were made available on demand this morning during the American Societyof Clinical Oncology (ASCO) Annual Meeting.
  • TG-1701 monotherapy was well tolerated and the maximum tolerated dose was not reached up to 400 mg QD.
  • TG Therapeuticsis a fully-integrated, commercial stage biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.
  • UKONIQ is a registered trademark of TG Therapeutics, Inc.
    UKONIQ is the first and onlyoral inhibitor of phosphoinositide 3 kinase (PI3K) delta and casein kinase 1(CK1) epsilon.

Diffusion Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update

Retrieved on: 
Monday, May 10, 2021

The study evaluated the safety and tolerability of TSC when administered every six hours for up to 15 days, a dosing regimen previously untested in a clinical trial setting.

Key Points: 
  • The study evaluated the safety and tolerability of TSC when administered every six hours for up to 15 days, a dosing regimen previously untested in a clinical trial setting.
  • Topline results, reported in mid-February 2021, showed that all doses evaluated were well tolerated and no dose-limiting toxicities or serious adverse events were observed.
  • Diffusion intends to initiate clinical studies in the identified indications during the first quarter of 2022.\nDiffusion Pharmaceuticals Inc. is an innovative biopharmaceutical company developing novel therapies that enhance the body\xe2\x80\x99s ability to deliver oxygen to areas where it is needed most.
  • In addition to TSC, Diffusion\xe2\x80\x99s product candidate DFN-529, a novel, allosteric PI3K/Akt/mTOR Pathway inhibitor, is in early-stage development.

Diffusion Pharmaceuticals Reports Final Results from Its Phase 1b Study of Trans Sodium Crocetinate in Hospitalized COVID-19 Patients

Retrieved on: 
Monday, May 10, 2021

In addition, no patients required dialysis or developed acute kidney injury and there were no reports of pulmonary embolism or deep vein thrombosis.

Key Points: 
  • In addition, no patients required dialysis or developed acute kidney injury and there were no reports of pulmonary embolism or deep vein thrombosis.
  • The medical and scientific communities have since come to understand COVID-19 is a much more complex disease, and the study itself was complicated to conduct.
  • The primary endpoint evaluates the relative change in TCOM readings from baseline after TSC administration.
  • In addition to TSC, Diffusion\xe2\x80\x99s product candidate DFN-529, a novel, allosteric PI3K/Akt/mTOR Pathway inhibitor, is in early-stage development.

Treadwell Announces Initiation of Patient Dosing in TWT-202, a Phase 1b/2 study of PLK4 Inhibitor, CFI-400945, in Patients with Leukemia

Retrieved on: 
Thursday, April 29, 2021

\xe2\x80\x9cPrevious clinical studies have shown that CFI-400945 can lead to single agent complete remissions in high-risk refractory AML patients.

Key Points: 
  • \xe2\x80\x9cPrevious clinical studies have shown that CFI-400945 can lead to single agent complete remissions in high-risk refractory AML patients.
  • The trial will enrol approximately 72 patients at up to 20 sites in North America and Asia.
  • PLK4 is overexpressed in a variety of solid tumors and elevated expression is associated with poor clinical outcomes.
  • CFI-400945 is a potent, selective, orally administered, first-in-class inhibitor of the serine/threonine kinase, polo-like kinase 4 (PLK4).

Rigel Announces Closing of Strategic Collaboration with Lilly

Retrieved on: 
Wednesday, April 7, 2021

Rigel and Lilly entered a global exclusive license agreement and strategic collaboration to co-develop and commercialize Rigel's R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for all indications including autoimmune and inflammatory diseases.

Key Points: 
  • Rigel and Lilly entered a global exclusive license agreement and strategic collaboration to co-develop and commercialize Rigel's R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for all indications including autoimmune and inflammatory diseases.
  • Pursuant to the collaboration, Lilly will also lead all clinical development of penetrating RIPK1 inhibitors in central nervous system (CNS) diseases.
  • The agreement is effective as of March 27, 2021and Rigel has received the$125 million upfront cash payment due under the terms of the agreement from Lilly.
  • Additional details about the collaboration can be found in Rigel's Form 8-K filed with the Securities and Exchange Commission on February 18, 2021.

ProMIS Neurosciences Announces Fiscal Year 2020 Results

Retrieved on: 
Wednesday, March 31, 2021

In May 2020, ProMIS announced it had identified novel antagonists against the receptor for activated protein kinase C1 (RACK1) that prevent the formation of dysfunctional protein aggregates andact torestore normal function.

Key Points: 
  • In May 2020, ProMIS announced it had identified novel antagonists against the receptor for activated protein kinase C1 (RACK1) that prevent the formation of dysfunctional protein aggregates andact torestore normal function.
  • In July 2020, the Company entered into two joint venture business arrangements (JV) with BC Neuroimmunology Lab, Inc. (BCNI).
  • In July 2020, the Company announced the voting results of the Corporation's annual meeting of shareholders held in Vancouver, BC.
  • In September 2020, ProMIS announced initiation of a program to construct and test a multivalent peptide vaccine for AD.

Diffusion Pharmaceuticals, Inc. to Present at the H.C. Wainwright Global Life Sciences Conference

Retrieved on: 
Thursday, March 4, 2021

Duringthepresentation, Dr. Cobuzzi willprovide an overview ofDiffusions recent corporate achievements, planned clinical trials, as well as potential milestones.

Key Points: 
  • Duringthepresentation, Dr. Cobuzzi willprovide an overview ofDiffusions recent corporate achievements, planned clinical trials, as well as potential milestones.
  • Our presentation will be available here , on the Investor Relations section of our website following the conference.
  • Diffusion Pharmaceuticals Inc. is an innovative biopharmaceutical company developing novel therapies that enhance the bodys ability to deliver oxygen to areas where it is needed most.
  • In addition to TSC, Diffusions product candidate DFN-529, a novel, allosteric PI3K/Akt/mTOR Pathway inhibitor, is in early-stage development.

Glycogen Synthase Kinase 3 (GSK3) inhibitor Pipeline Insight 2021: Key Players Involved are AMO Pharma, Actuate Therapeutics, Rock Creek Pharmaceuticals, BCN Biosciences & HitGen - ResearchAndMarkets.com

Retrieved on: 
Friday, February 19, 2021

The "Glycogen Synthase Kinase 3 (GSK3) inhibitor - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Glycogen Synthase Kinase 3 (GSK3) inhibitor - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "Glycogen Synthase Kinase 3 (GSK3) inhibitor - Pipeline Insight, 2021," report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Glycogen Synthase Kinase 3 (GSK3) inhibitor pipeline landscape.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Glycogen Synthase Kinase 3 (GSK3) inhibitor R&D.
  • Glycogen Synthase Kinase 3 (GSK3) inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.